hit counter
CymaBay Therapeutics, Inc. (CBAY) Stock News Sentiment & Price - Sentifly
CBAY - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



CymaBay Therapeutics, Inc. (CBAY)

USA
Biotechnology
NASDAQ
CBAY Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CBAY Latest news
GlobeNewsWire
Neutral
CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
2021-11-11 08:00

Webinar on Monday, November 15th, @ 4:30pm EST Webinar on Monday, November 15th, @ 4:30pm EST

Seeking Alpha
Neutral
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript
2021-11-10 21:13

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates
2021-11-10 19:05

CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -13.79% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update
2021-11-10 16:06

Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC)

GlobeNewsWire
Neutral
CymaBay Therapeutics to Present at Upcoming Investor Conferences
2021-11-04 08:00

NEWARK, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including the Credit Suisse 30th Annual Healthcare Conference taking place November 8-11, 2021, the Evercore ISI 4th Annual HealthCONx Conference taking place November 30 – December 2, 2021 and the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30 – December 2, 2021.

GlobeNewsWire
Neutral
CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
2021-11-03 16:05

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2021 and to provide a business update.

InvestorPlace
Positive
7 Penny Stocks With the Potential to 10X in 2022
2021-10-29 12:47

The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appeared first on InvestorPlace.

Seeking Alpha
Neutral
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript
2021-08-12 22:21

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
2021-08-12 16:06

Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth

GlobeNewsWire
Neutral
CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
2021-08-05 16:01

NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 12, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2021 and to provide a business update.

Loading more news...